Story thread · 3 reports / 3 sources
FDA extends review of Exelixis' colorectal cancer drug candidate
endpts.com · 3d
California-based drug developer Exelixis submitted new safety and efficacy data on its potential treatment of metastatic colorectal cancer (mCRC) to the FDA. The new data led to a three-month extension in the agency's review, the ...
First report: Exelixis stock falls as FDA extends zanzalintinib review — investing.com, 3d
The coverage
- Exelixis zanzalintinib NDA review extended three months by FDA
seekingalpha.com · 3d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.